Symbols / BRNS $0.68 -0.01%
BRNS Chart
About
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 27.76M |
| Enterprise Value | -31.31M | Income | -66.43M | Sales | — |
| Book/sh | 1.82 | Cash/sh | 1.73 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.59 | PEG | — |
| P/S | — | P/B | 0.37 | P/C | — |
| EV/EBITDA | 0.57 | EV/Sales | — | Quick Ratio | 7.16 |
| Current Ratio | 7.76 | Debt/Eq | 15.19 | LT Debt/Eq | — |
| EPS (ttm) | -1.88 | EPS next Y | -1.15 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-13 08:00 | ROA | -28.08% |
| ROE | -65.02% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 40.83M |
| Shs Float | 36.05M | Short Float | 0.03% | Short Ratio | 0.13 |
| Short Interest | — | 52W High | 2.92 | 52W Low | 0.56 |
| Beta | -0.62 | Avg Volume | 52.12K | Volume | 450.00 |
| Target Price | $5.50 | Recom | Strong_buy | Prev Close | $0.68 |
| Price | $0.68 | Change | -0.01% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.50
Mean price target
2. Current target
$0.68
Latest analyst target
3. DCF / Fair value
$-12.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.68
Low
$4.00
High
$7.00
Mean
$5.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-17 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-21 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-01-13 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-11-19 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-10-01 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-09-26 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-08-13 | main | Alliance Global Partners | Buy → Buy | $10 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-06-13 | main | Barclays | — → Overweight | $3 |
| 2024-06-07 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-04-22 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-04-19 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-03-21 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2023-11-28 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-09-25 | init | Alliance Global Partners | — → Buy | $12 |
| 2023-09-25 | down | Morgan Stanley | Overweight → Equal-Weight | $3 |
| 2023-08-18 | main | Morgan Stanley | Overweight → Overweight | $14 |
| 2023-06-13 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
- Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders? - Stock Titan Mon, 16 Mar 2026 23
- Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders? - The Killeen Daily Herald Mon, 16 Mar 2026 23
- 12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm Sat, 14 Mar 2026 20
- BRNS: SNAP-TI platform drives a robust pipeline in autoimmunity, with a merger set to expand clinical reach - TradingView Fri, 13 Mar 2026 16
- Barinthus Bio Announces 2025 Results and Clywedog Merger - TipRanks Fri, 13 Mar 2026 12
- Barinthus Biotherapeutics (NASDAQ: BRNS) posts 2025 loss, pushes ahead with Clywedog all-stock merger - Stock Titan Fri, 13 Mar 2026 12
- Barinthus Bio and Clywedog to merge in all-stock deal - Investing.com ue, 30 Sep 2025 07
- Barinthus Biotherapeutics 2025 10-K: $0M Revenue, $(66.5)M Net Loss - TradingView Fri, 13 Mar 2026 12
- 12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga ue, 10 Mar 2026 21
- Here's Why We're Not Too Worried About Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation - Yahoo Finance Sat, 26 Apr 2025 07
- BRNS Forecast — Price Prediction for 2026. Should I Buy BRNS? - Intellectia AI ue, 27 May 2025 06
- Barinthus Biotherapeutics Amends Cross-Border Merger Agreement Terms - TipRanks Mon, 23 Feb 2026 08
- BRNS - Barinthus Biotherapeutics plc Latest Stock News & Market Updates - Stock Titan Wed, 07 May 2025 07
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga ue, 10 Feb 2026 08
- US Exchange Insights: 3 Penny Stocks With Over $40M Market Cap - Yahoo Finance Mon, 03 Feb 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -8.55K | 0.00 | 0.00 | -4.55K |
| TaxRateForCalcs | 0.00 | 0.04 | 0.19 | 0.00 |
| NormalizedEBITDA | -43.16M | -71.06M | 5.19M | -40.28M |
| TotalUnusualItems | -12.21M | 0.00 | 0.00 | -7.59M |
| TotalUnusualItemsExcludingGoodwill | -12.21M | 0.00 | 0.00 | -7.59M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -61.07M | -73.35M | 5.34M | -50.87M |
| ReconciledDepreciation | 5.80M | 5.43M | 4.32M | 602.00K |
| EBITDA | -55.37M | -71.06M | 5.19M | -47.87M |
| EBIT | -61.17M | -76.49M | 869.00K | -48.47M |
| NetInterestIncome | 2.62M | 2.85M | 3.08M | -2.67M |
| InterestExpense | 53.00K | 28.00K | 19.00K | 2.67M |
| InterestIncome | 2.68M | 2.88M | 3.10M | 2.00K |
| NormalizedIncome | -48.87M | -73.35M | 5.34M | -43.28M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -61.07M | -73.35M | 5.34M | -50.87M |
| TotalExpenses | 66.75M | 81.25M | 47.50M | 41.49M |
| TotalOperatingIncomeAsReported | -67.97M | -83.91M | -4.04M | -45.22M |
| DilutedAverageShares | 39.35M | 38.39M | 38.17M | 25.89M |
| BasicAverageShares | 39.35M | 38.39M | 37.25M | 25.89M |
| DilutedEPS | -1.55 | -1.91 | 0.14 | -1.96 |
| BasicEPS | -1.55 | -1.91 | 0.14 | -1.96 |
| DilutedNIAvailtoComStockholders | -61.07M | -73.35M | 5.34M | -50.87M |
| NetIncomeCommonStockholders | -61.07M | -73.35M | 5.34M | -50.87M |
| NetIncome | -61.07M | -73.35M | 5.34M | -50.87M |
| MinorityInterests | 109.00K | 100.00K | 21.00K | 247.00K |
| NetIncomeIncludingNoncontrollingInterests | -61.18M | -73.45M | 5.32M | -51.11M |
| NetIncomeContinuousOperations | -61.18M | -73.45M | 5.32M | -51.11M |
| TaxProvision | -44.00K | -3.08M | -4.47M | -28.00K |
| PretaxIncome | -61.23M | -76.52M | 850.00K | -51.14M |
| OtherIncomeExpense | -12.07M | 1.08M | 567.00K | -7.25M |
| OtherNonOperatingIncomeExpenses | 135.00K | 1.08M | 567.00K | 332.00K |
| SpecialIncomeCharges | -12.21M | 0.00 | 0.00 | -13.79M |
| OtherSpecialCharges | 13.79M | |||
| ImpairmentOfCapitalAssets | 12.21M | 0.00 | ||
| GainOnSaleOfSecurity | 6.20M | |||
| NetNonOperatingInterestIncomeExpense | 2.62M | 2.85M | 3.08M | -2.67M |
| InterestExpenseNonOperating | 53.00K | 28.00K | 19.00K | 2.67M |
| InterestIncomeNonOperating | 2.68M | 2.88M | 3.10M | 2.00K |
| OperatingIncome | -51.78M | -80.45M | -2.80M | -41.22M |
| OperatingExpense | 66.75M | 81.25M | 47.50M | 41.49M |
| OtherOperatingExpenses | -1.18M | |||
| ResearchAndDevelopment | 38.25M | 41.41M | 41.11M | 16.37M |
| SellingGeneralAndAdministration | 29.67M | 39.84M | 6.39M | 25.12M |
| GeneralAndAdministrativeExpense | 29.67M | 39.84M | 6.39M | 25.12M |
| OtherGandA | 29.67M | 39.84M | 6.39M | 25.12M |
| TotalRevenue | 14.97M | 802.00K | 44.70M | 268.00K |
| OperatingRevenue | 14.97M | 802.00K | 44.70M | 268.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 40.23M | 38.64M | 37.68M | 37.19M |
| ShareIssued | 40.23M | 38.64M | 37.68M | 37.19M |
| TotalDebt | 12.01M | 12.98M | 8.77M | 7.22M |
| TangibleBookValue | 108.08M | 149.47M | 202.42M | 208.06M |
| InvestedCapital | 130.03M | 186.78M | 242.90M | 252.28M |
| WorkingCapital | 110.08M | 144.31M | 200.80M | 215.61M |
| NetTangibleAssets | 108.08M | 149.47M | 202.42M | 208.06M |
| CapitalLeaseObligations | 12.01M | 12.98M | 8.77M | 7.06M |
| CommonStockEquity | 130.03M | 186.78M | 242.90M | 252.12M |
| TotalCapitalization | 130.03M | 186.78M | 242.90M | 252.12M |
| TotalEquityGrossMinorityInterest | 130.13M | 187.00M | 243.20M | 252.56M |
| MinorityInterest | 106.00K | 211.00K | 305.00K | 437.00K |
| StockholdersEquity | 130.03M | 186.78M | 242.90M | 252.12M |
| OtherEquityInterest | 86.00K | 86.00K | 94.00K | 94.00K |
| GainsLossesNotAffectingRetainedEarnings | -25.87M | -23.32M | -33.46M | -8.49M |
| ForeignCurrencyTranslationAdjustments | -25.87M | -23.32M | -33.46M | -8.49M |
| RetainedEarnings | -237.66M | -176.59M | -103.24M | -108.58M |
| AdditionalPaidInCapital | 393.47M | 386.60M | 379.50M | 369.10M |
| CapitalStock | 1.00K | 1.00K | 1.00K | 1.00K |
| CommonStock | 1.00K | 1.00K | 1.00K | 1.00K |
| TotalLiabilitiesNetMinorityInterest | 30.19M | 27.51M | 27.00M | 28.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 14.54M | 14.91M | 14.76M | 17.00M |
| OtherNonCurrentLiabilities | 4.01M | 3.15M | 2.68M | 2.37M |
| NonCurrentDeferredLiabilities | 438.00K | 574.00K | 3.75M | 8.08M |
| NonCurrentDeferredTaxesLiabilities | 438.00K | 574.00K | 3.75M | 8.08M |
| LongTermDebtAndCapitalLeaseObligation | 10.09M | 11.19M | 8.34M | 6.54M |
| LongTermCapitalLeaseObligation | 10.09M | 11.19M | 8.34M | 6.54M |
| CurrentLiabilities | 15.66M | 12.60M | 12.24M | 11.16M |
| CurrentDeferredLiabilities | 1.74M | 0.00 | 0.00 | 182.00K |
| CurrentDeferredRevenue | 1.74M | 0.00 | 0.00 | 182.00K |
| CurrentDebtAndCapitalLeaseObligation | 1.92M | 1.78M | 433.00K | 682.00K |
| CurrentCapitalLeaseObligation | 1.92M | 1.78M | 433.00K | 523.00K |
| CurrentDebt | 159.00K | |||
| OtherCurrentBorrowings | 159.00K | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.77M | 2.41M | 1.93M | 1.42M |
| PayablesAndAccruedExpenses | 10.22M | 8.40M | 9.88M | 8.87M |
| CurrentAccruedExpenses | 5.33M | 6.80M | 6.14M | 6.45M |
| Payables | 4.89M | 1.60M | 3.75M | 2.42M |
| TotalTaxPayable | 2.42M | 0.00 | ||
| AccountsPayable | 2.47M | 1.60M | 3.75M | 2.42M |
| TotalAssets | 160.33M | 214.51M | 270.20M | 280.71M |
| TotalNonCurrentAssets | 34.59M | 57.60M | 57.16M | 53.95M |
| OtherNonCurrentAssets | 881.00K | 882.00K | 976.00K | 804.00K |
| GoodwillAndOtherIntangibleAssets | 21.95M | 37.32M | 40.48M | 44.06M |
| OtherIntangibleAssets | 21.95M | 25.11M | 28.27M | 31.43M |
| Goodwill | 0.00 | 12.21M | 12.21M | 12.63M |
| NetPPE | 11.76M | 19.40M | 15.71M | 9.09M |
| AccumulatedDepreciation | -9.42M | -3.69M | -1.32M | -886.00K |
| GrossPPE | 21.18M | 23.09M | 17.03M | 9.97M |
| Leases | 9.28M | 8.67M | 3.93M | 628.00K |
| OtherProperties | 10.56M | 13.31M | 12.06M | 9.11M |
| MachineryFurnitureEquipment | 1.33M | 1.11M | 1.04M | 232.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 125.74M | 156.91M | 213.04M | 226.76M |
| OtherCurrentAssets | 344.00K | 1.47M | 611.00K | 995.00K |
| RestrictedCash | 1.74M | 0.00 | ||
| PrepaidAssets | 5.89M | 4.61M | ||
| Receivables | 13.00M | 13.34M | 18.05M | 11.72M |
| OtherReceivables | 13.00M | 10.31M | 12.20M | 10.84M |
| DuefromRelatedPartiesCurrent | 5.52M | 0.00 | ||
| TaxesReceivable | 0.00 | 3.03M | 0.00 | 855.00K |
| AccountsReceivable | 0.00 | 5.85M | 20.00K | |
| CashCashEquivalentsAndShortTermInvestments | 110.66M | 142.09M | 194.38M | 214.05M |
| CashAndCashEquivalents | 110.66M | 142.09M | 194.38M | 214.05M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -29.83M | -56.34M | -20.57M | -33.73M |
| RepaymentOfDebt | 0.00 | -159.00K | 0.00 | |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 2.16M | 2.04M | 484.00K | 228.01M |
| CapitalExpenditure | -892.00K | -5.41M | -6.14M | -1.15M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 1.84M | |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 152.00K | |
| EndCashPosition | 112.40M | 142.09M | 194.38M | 214.05M |
| BeginningCashPosition | 142.09M | 194.38M | 214.05M | 43.27M |
| EffectOfExchangeRateChanges | -2.02M | 2.17M | 187.00K | -6.46M |
| ChangesInCash | -27.67M | -54.47M | -19.86M | 177.25M |
| FinancingCashFlow | 2.16M | 1.87M | 325.00K | 222.74M |
| CashFlowFromContinuingFinancingActivities | 2.16M | 1.87M | 325.00K | 222.74M |
| NetOtherFinancingCharges | -163.00K | -5.27M | ||
| ProceedsFromStockOptionExercised | 0.00 | 0.00 | 0.00 | |
| NetPreferredStockIssuance | 0.00 | 125.24M | ||
| PreferredStockIssuance | 0.00 | 125.24M | ||
| NetCommonStockIssuance | 2.16M | 2.04M | 484.00K | 102.77M |
| CommonStockIssuance | 2.16M | 2.04M | 484.00K | 102.77M |
| NetIssuancePaymentsOfDebt | 0.00 | -159.00K | 0.00 | |
| NetShortTermDebtIssuance | -159.00K | 0.00 | ||
| ShortTermDebtPayments | -159.00K | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | -159.00K | 0.00 | |
| LongTermDebtPayments | 0.00 | -159.00K | 0.00 | |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -892.00K | -5.41M | -5.75M | -12.91M |
| CashFlowFromContinuingInvestingActivities | -892.00K | -5.41M | -5.75M | -12.91M |
| NetBusinessPurchaseAndSale | 0.00 | -11.77M | ||
| PurchaseOfBusiness | 0.00 | -11.77M | ||
| NetPPEPurchaseAndSale | -892.00K | -5.41M | -5.75M | -1.15M |
| SaleOfPPE | 0.00 | 388.00K | 0.00 | |
| PurchaseOfPPE | -892.00K | -5.41M | -6.14M | -1.15M |
| OperatingCashFlow | -28.94M | -50.92M | -14.43M | -32.58M |
| CashFlowFromContinuingOperatingActivities | -28.94M | -50.92M | -14.43M | -32.58M |
| ChangeInWorkingCapital | 2.60M | 6.17M | -5.52M | -7.18M |
| ChangeInOtherWorkingCapital | 1.74M | -183.00K | -63.00K | |
| ChangeInOtherCurrentLiabilities | -1.79M | -445.00K | 0.00 | |
| ChangeInOtherCurrentAssets | 0.00 | 128.00K | -387.00K | -735.00K |
| ChangeInPayablesAndAccruedExpense | 1.35M | -1.39M | 1.89M | 889.00K |
| ChangeInAccruedExpense | 456.00K | 1.99M | 751.00K | 4.42M |
| ChangeInPayable | 898.00K | -3.38M | 1.14M | -3.53M |
| ChangeInAccountPayable | 898.00K | -3.38M | 1.14M | -3.53M |
| ChangeInPrepaidAssets | 3.64M | 2.20M | -2.17M | -4.22M |
| ChangeInReceivables | -2.35M | 5.67M | -4.67M | -3.05M |
| ChangesInAccountReceivables | 0.00 | 5.80M | -5.83M | 559.00K |
| OtherNonCashItems | 2.36M | 1.41M | 1.16M | 1.15M |
| StockBasedCompensation | 4.71M | 5.05M | 9.88M | 16.49M |
| AssetImpairmentCharge | 17.47M | 0.00 | ||
| DeferredTax | -44.00K | -3.08M | -4.34M | -119.00K |
| DeferredIncomeTax | -44.00K | -3.08M | -4.34M | -119.00K |
| DepreciationAmortizationDepletion | 5.80M | 5.43M | 4.32M | 602.00K |
| DepreciationAndAmortization | 5.80M | 5.43M | 4.32M | 602.00K |
| OperatingGainsLosses | -649.00K | 7.53M | -25.25M | 7.59M |
| GainLossOnInvestmentSecurities | -5.99M | |||
| NetForeignCurrencyExchangeGainLoss | -649.00K | 7.53M | -24.91M | -209.00K |
| GainLossOnSaleOfPPE | 0.00 | -348.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -61.18M | -73.45M | 5.32M | -51.11M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BRNS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|